shimonv
Trusted Information Resource
Hi Fellows,
Background
-There is this product that is packaged in a blister and sterilized in EtO.
-The current version is an adaptation of the previous version (the did not repeat the validation).
-The previous version was validated, and that included multiple cycles of sterilizations.
Situation
A functional problem was identified with the current version which requires re-opening and repair.
Questions:
1. Does the standards provide guidance on such circumstances?
2. I can think of two challenges: the effect on material and residual EtO levels after a second sterilization. The material is the same a as the previous model. Would it be sufficient to write a rationale based on similarities, and if so what are the key points to address?
One last note: this product is being used in clinical trials in Europe; it is not a commercial product.
Thanks in advance,
Shimon
Background
-There is this product that is packaged in a blister and sterilized in EtO.
-The current version is an adaptation of the previous version (the did not repeat the validation).
-The previous version was validated, and that included multiple cycles of sterilizations.
Situation
A functional problem was identified with the current version which requires re-opening and repair.
Questions:
1. Does the standards provide guidance on such circumstances?
2. I can think of two challenges: the effect on material and residual EtO levels after a second sterilization. The material is the same a as the previous model. Would it be sufficient to write a rationale based on similarities, and if so what are the key points to address?
One last note: this product is being used in clinical trials in Europe; it is not a commercial product.
Thanks in advance,
Shimon